Otilonium bromide in irritable bowel syndrome: A double-blind, placebo-controlled, 15-week study

Alimentary Pharmacology and Therapeutics

Volumn 12, Issue 10, 1998, Pages 1003-1010

  Battaglia, G ^a,f   Morselli Labate, A M ^b   Camarri, E ^c   Francavilla, A ^d   De Marco, F ^d   Mastropaolo, G ^e   Naccarato, R ^e  

^a Hospital 'SS Giovanni e Paolo'   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Grosseto Hospital   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f Unit of Gastroenterology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OTILONIUM BROMIDE; SPASMOLYTIC AGENT;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ARTICLE; BARIUM ENEMA; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENDOSCOPY; FEMALE; HUMAN; IRRITABLE COLON; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SIGMOID; WELLBEING;

COLONIC DISEASES, FUNCTIONAL; DOUBLE-BLIND METHOD; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PAIN; PARASYMPATHOLYTICS; PLACEBOS; QUATERNARY AMMONIUM COMPOUNDS;

EID: 0031663620     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1998.00397.x     Document Type: Article

References (23)

1. Harvey FRD, Salih SY, Read AE. Organic and functional disorders in 2000 gastroenterology outpatients. Lancet 1983; i: 632-4.
2. Thompson WG. The irritable bowel. Gut 1984; 25: 305-20.
3. Drossman DA, McKee DC, Sandler RS, et al. Psychosocial factors in the irritable bowel syndrome. A multivariate analysis of patients and non-patients with irritable bowel syndrome. Gastroenterology 1988; M95: 701-8.
4. Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995; 109: 1736-41.
5. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J 1978; 3: 762-3.
6. Thompson WG, Dotevall G, Drossman DA, Heaton KW, Kruis W. Irritable bowel syndrome (IBS): guidelines for the diagnosis. Roma 88 Working team report presented at the International Congress of Gastroenterology, Rome, 1988.
7. Whitehead WE, Crowell MD, Bosmajian L, et al. Existence of irritable bowel syndrome supported by factor analysis of symptoms in two community samples. Gastroenterology 1990; 98: 336-40.
8. Talley NJ, Philips SF, Melton LJ, Mulvihill C, Wiltgen C, Zinsmeister AR. Diagnostic value of the Manning criteria in irritable bowel syndrome. Gut 1990; 31: 77-81.
9. Smith RC, Greenbaum DS, Vancouver JB, et al. Gender differences in Manning criteria in the irritable bowel syndrome. Gastroenterology 1991; 100: 591-5.
10. Talley NJ, Phillips SF, Bruce B, Zinsmeister AR, Wiltgen C, Melton LJ. Multisystem complaints in patients with the irritable bowel syndrome and functional dyspepsia. Eur J Gastroenterol Hepatol 1991; 3: 71-7.
11. Maxton DG, Morris J, Whorwell PJ. More accurate diagnosis of irritable bowel syndrome by the use of "non-colonic" symptomatology. Gut 1991; 32: 784-6.
12. Drossman DA, Grant Thomson W, Talley NJ, Funch-Jensen P, Janssen J, Whitehead WE. Identification of sub-groups of functional gastrointestinal disorders. Gastroenterol Int 1990; 3: 159-72.
13. Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1988; 95: 232-41.
14. Cooper HL. Irritable Bowel Syndrome: diagnosis by exclusion. Geriatrics 1980; 35: 43-6.
15. Dobrilla G, Imbimbo BP, Piazzi L, Bensi G. Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial. Gut 1990; 31: 355-8.
16. Maggi CA, Manzini S, Meli A. Otilonium bromide: a smooth muscle relaxant which interferes with calcium mobilization. Arch Int Pharmacodyn 1983; 264: 305-23.
17. Maggi CA, Meli A. Assessment of potential selectivity of antispasmodics for the various sections of the gastro-intestinal tract of the rat as a guideline for their clinical use. Arch Int Pharmacodyn 1983; 262: 221-30.
18. Giachetti A. Pharmacological studies on otilonium bromide. Ital J Gastroenterol 1991; 23(Suppl. 1): 56-9.
19. Manzini S, Maggi CA, Parlani M, Subissi A, Meli A. Further studies on the pharmacodynamic properties and organ selectivity of otilonium bromide. Drugs Exp Clin Res 1988; 14: 265-70.
20. Manzini S, Maggi CA, Meli A. System and organ selectivity of smooth relaxants or in vitro spontaneously contracting preparations. Arch Int Pharmacodyn 1984; 270: 50-60.
21. Castiglione F, Daniele B, Mazzacca G. Therapeutic strategy for the irritable bowel syndrome. Ital J Gastroenterol 1991; 23(Suppl. 1): 53-5.
22. Baldi F, Otilonium bromide in the treatment of the Irritable Bowel Syndrome: a clinical-functional study. Hepatogastroenterology 1992; 39: 392-5.
23. Norusis M, SPSS Inc. SPSS/PC+ 4.0 Base, Statistics and Advanced Statistics Manuals. Chicago: SPSS Inc, 1990.